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Reactive oxygen speciesThe post-translational modiﬁcation of serine and threonine residues of nuclear and cytoplasmic proteins by the
O-linked attachment of the monosaccharide β-N-acetyl-glucosamine (O-GlcNAc) is emerging as an important
mechanism for the regulation of numerous biological processes critical for normal cell function. Active synthesis
of O-GlcNAc is essential for cell viability and acute activation of pathways resulting in increasedproteinO-GlcNAc
levels improves the tolerance of cells to a wide range of stress stimuli. Conversely sustained increases in O-
GlcNAc levels have been implicated in numerous chronic disease states, especially as a pathogenic contributor
to diabetic complications. There has been increasing interest in the role of O-GlcNAc in the heart and vascular
system and acute activation of O-GlcNAc levels have been shown to reduce ischemia/reperfusion injury, attenu-
ate vascular injury responses as well mediate some of the detrimental effects of diabetes and hypertension on
cardiac and vascular function. Hereweprovide an overviewof our current understanding of pathways regulating
protein O-GlcNAcylation, summarize the different methodologies for identifying and characterizing O-
GlcNAcylated proteins and subsequently focus on two emerging areas: 1) the role of O-GlcNAc as a potential reg-
ulator of cardiac metabolism and 2) the cross talk between O-GlcNAc and reactive oxygen species. This article is
part of a Special Section entitled “Post-translational Modiﬁcation.”llular Pathology, Department of
niversity Boulevard, Volker Hall
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Classical protein glycosylation involves the synthesis of complex
elongated oligosaccharide structures via N-linkage on asparagine
and O-linkage on the hydroxy amino acids serine (Ser) and threonine
(Thr), as well as hydroxyproline, hydroxylysine, and tyrosine residues
Fig. 1. The hexosamine biosynthesis pathway (HBP) and protein O-GlcNAcylation. Glu-
cose imported into the cells is rapidly phosphorylated to glucose-6-phosphate and con-
verted to fructose-6-phosphate, which is subsequently metabolized to glucosamine-6-
phosphate by L-glutamine-D-fructose 6-phosphate amidotransferase (GFAT). Synthesis
of glucosamine-6-phosphate is dependent on availability of glutamine, which is formed
by glutamine synthetase (GTS). Glucosamine-6-phosphate is subsequently metabolized
by glucosamine 6-phosphate N-acetyltransferase (Emeg32) to N-acetylglucosamine-6-
phosphate, which is converted to N-acetylglucosamine-1-phosphate by phosphoacetyl-
glucosamine mutase (Agm1) and the synthesis of UDP-uridine-diphosphate-N-acetylglu-
cosamine (UDP-GlcNAc) is catalyzed by UDP-N-acetylglucosamine pyrophosphorylase
(Uap1). Flux through the HBP can be increased with glucosamine, which is phosphorylat-
ed by hexokinase (HK) to form glucosamine 6-phosphate thereby bypassing GFAT. UDP-
GlcNAc is the obligatory substrate for OGT (uridine-diphospho-N-acetylglucosamine:
polypeptide β-N-acetylglucosaminyltransferase) leading to the formation of O-linked β-
N-acetylglucosamine (O-GlcNAc)-modiﬁed proteins. β-N-acetylglucosaminidase (OGA)
catalyzes the removal of O-GlcNAc from the proteins.
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teins [1]. Importantly these glycosylation reactions occur exclusively
in the ER and Golgi; however, in 1984 a novel glycosylation modiﬁca-
tion was ﬁrst reported in which a single β-N-acetyl-glucosamine moi-
ety was attached via an O-linkage to serine (Ser) and threonine (Thr)
residues of cytoplasmic and nuclear proteins [2]. This modiﬁcation,
now commonly known as O-GlcNAc, has been shown to be present
in over 1000 nuclear, cytoplasmic and mitochondrial proteins and
has been found in all metazoans, as well as in some bacteria, protozoa,
viruses and fungi [3–7]. O-GlcNAcylation is distinct from traditional
glycosylation in that it is restricted to the cytoplasm, nucleus and mi-
tochondria and it is not extended into complex elongated structures;
it also exhibits parallels with protein phosphorylation, in that it re-
sponds to acute stimuli, alters protein function and enzyme activity
and modiﬁes the same or proximal Ser/Thr residues as phosphoryla-
tion [3–7].
It has become increasingly apparent that O-GlcNAc modiﬁcation
of proteins is an important mechanism for the regulation of numer-
ous biological processes critical for normal cell function such as signal
transduction [8–11], proteasome activity [12,13], apoptosis [14,15],
nuclear transport [16], translation and transcription [17]. Most of
our understanding of the impact of alterations in O-GlcNAc levels
on cell function has come from studies of chronic disease models
such as cancer [18–20], senescence [21–23], neurodegeneration
[11,14,24,25] as well as diabetes and diabetic complications [26,27].
However, a number of studies have demonstrated that O-GlcNAc is
essential for cell viability [28–30] and that acute activation of path-
ways resulting in increased protein O-GlcNAc levels improves the tol-
erance of cells to a wide range of stress stimuli [29].
There has been increasing interest in the role of O-GlcNAc in the
heart and vascular system and acute activation of O-GlcNAc levels has
been shown to reduce ischemia/reperfusion injury [31–41], attenuate
vascular injury responses [42] as well mediate some of the detrimental
effects of diabetes [21,43–49] and hypertension [50–53] on cardiac and
vascular function. The growing awareness of the effects of altered O-
GlcNAc on cardiovascular function is reﬂected in part by a relatively
large number of reviews on this subject over the past few years
[37,52–58]. Therefore, in light of these and other recent comprehensive
reviews on O-GlcNAc biology [3–7], we provide a brief summary on the
regulation of O-GlcNAc synthesis, followed by a practical overview re-
garding the 1) modulation of cellular O-GlcNAc levels and 2) the char-
acterization and identiﬁcation of O-GlcNAcylated proteins. We then
focus on two emerging areas, namely the role of O-GlcNAc as a potential
regulator of cardiac metabolism and the cross talk between O-GlcNAc
and reactive oxygen species, with an emphasis on the role of mitochon-
dria in mediating this interaction.
2. Regulation of O-GlcNAc synthesis and turnover
The primary components involved in regulating O-GlcNAc synthe-
sis and turnover are summarized in Fig. 1. Uridine-diphosphate-N-
acetylglucosamine (UDP-GlcNAc) is the sugar nucleotide donor for
the synthesis of O-GlcNAc modiﬁed proteins, by O-GlcNAc transferase
(OGT). OGT has a high afﬁnity for UDP-GlcNAc, which provides it with
a competitive advantage over nucleotide transporters in the endo-
plasmic reticulum and Golgi that compete for cytoplasmic UDP-
GlcNAc, but also makes it highly sensitive to changes in UDP-GlcNAc
concentrations [59]. Thus, the rate of O-GlcNAc synthesis and overall
levels of O-GlcNAc protein modiﬁcation are highly dependent on the
ﬂux through hexosamine biosynthesis pathway (HBP). HBP ﬂux is
regulated largely by L-glutamine-D-fructose 6-phosphate amidotrans-
ferase (GFAT), which converts fructose-6-phosphate to glucosamine-
6-phosphate with glutamine as the amine donor [60].
Cell culture studies suggest that ~2–5% of total glucose entering the
cell is metabolized via GFAT [61]; however, the extent to which this
holds true for a highly metabolic organ, such as the heart is unknown.GFAT is considered to be the primary rate-determining step in the
HBP and exists in two isoforms (GFAT1 and GFAT2), transcribed from
separate genes. In the heart GFAT2 is the most abundant isoform [62]
and in rodent models of aging [23] and pressure overload hypertrophy
[63] there were signiﬁcant increases in GFAT2mRNA levels, but little or
no change in GFAT1 mRNA levels. In both studies there were also in-
creased UDP-GlcNAc levels, consistent with an increase in HBP ﬂux,
suggesting that GFAT expression and HBP ﬂux in the heart are subject
to regulation in response to chronic stress. It is also of note that both
GFAT1 and GFAT2 are subject to phosphorylation by cAMP-dependent
protein kinase [64,65]; in addition both AMPK and CaMKII lead to phos-
phorylation of Ser243 of human GFAT1 resulting in increased enzyme
activity [66].While our understanding of the regulation of GFAT activity
remains poorly understood, the fact that it appears to be a target for
AMPK, raises the possibility that it is a key link between AMPK, the
HBP and O-GlcNAc signaling.
Following its synthesis by GFAT, glucosamine-6-phosphate is me-
tabolized via glucosamine 6-phosphate N-acetyltransferase (Emeg32),
phosphoacetylglucosamine mutase (Agm1) and ﬁnally UDP-N-
acetylglucosamine pyrophosphorylase (Uap1) to UDP-GlcNAc (Fig. 1).
The HBP is often referred to as a “nutrient-sensing” pathway, and this
highlighted by the fact that in addition to glucose availability, UDP-
GlcNAc synthesis is dependent on amino acid metabolism, speciﬁcally
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or fatty acid metabolism as well as high energy phosphates in the
form of ATP and UTP. Thus, the synthesis of UDP-GlcNAc is critically de-
pendent on the coordinated action of several keymetabolic pathways in
addition to glucose. The importance of the HBP and UDP-GlcNAc syn-
thesis for cell viability is also emphasized by the fact that gene deletion
of either EMeg32 or Agm1 is embryonically lethal [67,68]; surprisingly
however, remarkably little is known about the regulation of HBP ﬂux
in the heart or indeed in other tissues.
In addition to being a substrate for traditional glycosylation, UDP-
GlcNAc is also a substrate for OGT, a unique glycosyl transferase,
which catalyzes the attachment of O-GlcNAc to speciﬁc Ser/Thr resi-
dues of nuclear and cytoplasmic proteins. In humans and mice there
is a single OGT gene located on the X chromosome [69–71], which
through alternative splicing leads to three isoforms: 1) nucleocyto-
plasmic, ncOGT, (100 kDa); 2) short form, sOGT (78 kDa) and 3) a
mitochondrial form, mOGT (103 kDa); each isoform has the same
C-terminal catalytic domains, but different N-terminal domains con-
tributing to different localization and targeting [69,70,72]. In muscle,
kidney and liver, OGT exists as a heterotrimer consisting of two 110 kDa
and one 78 kDa subunits [73]; in other tissues it is a homotrimer of three
110 kDa subunits [71]. The catalytic C-terminal domain is altered by tyro-
sine phosphorylation and is also a target for O-GlcNAcylation [71], sug-
gesting a potential feedback regulatory element on OGT activity. Later
wewill discuss inmore detail the fact that insulin increases both tyrosine
phosphorylation and O-GlcNAcylation of OGT, leading to increased activ-
ity and transient translocation from nucleus to cytoplasm [74,75]. The N-
terminal domain of OGT contains multiple tetratricopeptide repeats
(TPR), which mediate the protein–protein interactions involved in the
recognition and activation of speciﬁc protein targets [59,76].
The steady state level of protein O-GlcNAcylation is dependent on
the rate of synthesis catalyzed by OGT as well as its rate of removal
catalyzed by β-N-acetylglucosaminidase (O-GlcNAcase) [77,78]. As
with OGT, O-GlcNAcase is highly conserved across species and is
expressed in all tissues and unlike lysosomal hexosaminidases has a
pH optimum in the neutral range, pH 4.5–6 [77,78]. Also similar to
OGT, O-GlcNAcase is also encoded by a single gene, with at least
two alternative spliced isoforms [6]. The predominant splice variants
are, a long N100 kDa form, and a short form (~70 kDa) with the O-
GlcNAcase catalytic regions in the N-terminal domain [6,79]. The C-
terminal region of the long isoform has a histone acetyl-transferase
like domain with a caspase cleavage site between the two regions
suggesting potential regulation in response to apoptosis; however,
cleavage per se does not appear to affect the O-GlcNAcase activity,
suggesting that this may have other regulatory roles, such as stabili-
zation, localization or targeting [80–82]. The short form of O-
GlcNAcase has a smaller C-terminal region and lacks the putative HAT
domain found in the long form [6,79]; little is known regarding the dif-
ferent functions or localization of these two O-GlcNAcase isoforms, al-
though the long isoform appears to exhibit greater catalytic activity
than the short isoform [79]. As with GFAT and OGT, our knowledge of
the regulation of O-GlcNAcase activity remains limited; however, it is
known to be both phosphorylated and modiﬁed by O-GlcNAc [78,80].
Changes in cellular O-GlcNAc levels occur rapidly, with a response
time of seconds to minutes in response to extracellular stimuli
[83,84], which not only distinguishes it from traditional forms of gly-
cosylation, but also draws parallels with phosphorylation. Further
similarities to phosphorylation are emphasized by the fact that O-
GlcNAc also modiﬁes Ser/Thr residues and in some cases phosphory-
lation and O-GlcNAcylation occur on the same residues. It is increas-
ingly evident that there is a complex and extensive cross talk
between O-GlcNAcylation and phosphorylation; for example, Wang
et al., [85] reported that increasing overall cellular O-GlcNAc levels
by inhibition of O-GlcNAcase decreased phosphorylation at 280 sites
and increased phosphorylation at 148 sites. The potential for rapid cy-
cling between O-GlcNAcylation and phosphorylation is furtheremphasized by the observations that OGT and O-GlcNAcase forms
transient complexes with kinases and protein phosphatases [86,87].
3. Pharmacological andmolecularmodulationofO-GlcNAc turnover
Experimentally O-GlcNAc levels can be increased by activating
synthesis, which is commonly achieved by elevating extracellular glu-
cose concentrations, adding extracellular glucosamine, or by prevent-
ing its removal by inhibiting O-GlcNAcase. Hyperglycemia (~25 mM
glucose) increases overall O-GlcNAc levels in many cell lines includ-
ing neonatal and adult cardiomyocytes [34,45,46]. While some of
the effects of hyperglycemia in cardiomyocytes can be reversed by in-
hibition of GFAT with either 6-diazo-5-oxo-L-norleucine (DON) or O-
diazoacetyl-L-serine (azaserine) [34,46], hyperglycemia clearly has
many other effects on cellular function other than increasing metab-
olism via the HBP. Additionally while azaserine and DON are com-
monly used as GFAT inhibitors, they are better characterized as
amidotransferase inhibitors [88]; thus, conclusions based on their
use should be made with caution. Glucosamine is readily transported
by the glucose transporter systems, with a Km of 2–4 mM for GLUT1
and GLUT4 [89], the primary glucose transporters in cardiomyocytes
and subsequently phosphorylated by hexokinase to glucosamine 6-
phosphate. Glucosamine 6-phosphate directly enters the HBP bypass-
ing the key regulatory enzyme GFAT (Fig. 1), resulting in an increase
in UDP-GlcNAc and O-GlcNAc levels. In the perfused heart, 5 mM glu-
cosamine leads to 2 to 3 fold increase in O-GlcNAc levels within
15 min [32] and as little as 100 μM glucosamine has been shown to
signiﬁcantly augment O-GlcNAc levels in the heart [90]. Such studies
highlight the dynamic nature of the HBP and O-GlcNAc synthesis in
the heart; however, increasing UDP-GlcNAc levels can also impact
the synthesis of other glycoconjugates [91,92] and elevated levels of
other intermediates in the HBP have the potential to alter other met-
abolic pathways such as glycogen synthesis [93]. Nevertheless, at the
cellular level increasing OGT protein levels appear to have the same
effects on cardiomyocytes as adding glucosamine [33,94], suggesting
that the predominant effect of glucosamine, at least in the short
term, is to increase cellular O-GlcNAc levels. Several studies have
reported that the addition of glucosamine results in depletion of ATP
levels [95]; however, we have not observed any impact of glucosamine
treatment on ATP levels in either cardiomyocytes or the intact perfused
heart [34,36,90]. Furthermore, up to 10 mM glucosamine also had no
adverse effect on cardiac function [90].
PUGNAc [O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-
N-phenylcarbamate] is a widely used competitive inhibitor of O-
GlcNAcase [96,97] and by attenuating the removal of O-GlcNAc leads
to signiﬁcant increases in cellular O-GlcNAc levels in isolated cardio-
myocytes, the isolated perfused heart and in vivo [31,34,38,98]. Al-
though a common tool for increasing O-GlcNAc levels PUGNAc is also
equally effective as an inhibitor of lysosomal hexosaminidases [99],
which raises concerns about is speciﬁcity. Recently two new classes of
O-GlcNAcase inhibitors have been described; GlcNAcastatin [100] and
NAG-thiazolines [99,101], both of which exhibit several orders of mag-
nitude of greater speciﬁcity for O-GlcNAcase over other hexosamini-
dases and with Ki in vitro in the pico to nanomolar range. We have
successfully used the NAG-thiazoline derivatives 1,2 dideoxy-2′-
propyl-α-D-glycopyranoso-[2,1-d]-Δ2′-thiazoline (NAG-Bt) and 1,2
dideoxy-2′-ethylamino-α-D-glucopyranoso-[2,1-d]-Δ2′thiazoline
(NAG-Ae) to increase O-GlcNAc levels in the perfused heart and
cardiomyocytes [37]. In the perfused heart NAG-Bt had an EC50 of
~30 μM for increasing overall O-GlcNAc levels [37]; in recent stud-
ies, in cardiomyocytes we found that NAG-Ae, also known as
thiamet-G, had an EC50 of ~100 nM for increasing O-GlcNAc levels
[102]. In addition to effectively increasing O-GlcNAc levels in isolat-
ed cardiomyocytes and hearts, preliminary studies in vivo demon-
strate that i.p. administration of thiamet-G at a dose of 50 mg/kg
resulted in a 2–3 fold increase in cardiac O-GlcNAc levels within
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noting that Yuzwa et al., [103] reported that thiamet-G added to
drinking water was effective at increasing tissue O-GlcNAc levels;
however, they did not report on the O-GlcNAc levels in the heart.
We have observed no detrimental effects of O-GlcNAcase inhibitors
on cardiac function in the perfused heart; thus, there appears to be
no acute adverse effects of increasing cardiac O-GlcNAc levels by
inhibiting O-GlcNAcase.
While it is possible to pharmacologically increase O-GlcNAc levels
by either increasing synthesis or inhibiting degradation, there are
limited options for decreasing O-GlcNAc levels. The most common
approach has been to attenuate OGT protein levels at the cellular
level either by using siRNA methods [33], increase O-GlcNAcase ex-
pression [40] or to delete OGT completely using Cre-lox technology
[30]. In cell culture, OGT-null mouse embryonic ﬁbroblasts (MEFs)
grow normally up to 48 h, after which growth slows and cell death
occurs around 4–5 days [30]. Watson et al., [104] reported the develop-
ment of a cardiac speciﬁc, inducible OGT KOmouse and found that a re-
duction in OGT levels had no adverse effects under basal conditions, but
did accelerate the development of contractile dysfunction in response
to pressure overload. The lack of any effects of decreased OGT levels in
the absence of additional stress was somewhat surprising, given that
OGT gene deletion typically leads to cell death [30]. The reason for
this lack of phenotype is unclear and could be linked to transduction
mosaicism or incomplete penetrance, which can occur in such induc-
ible models, or that while OGT levels are markedly lower, that there
has been an adaptive response leading to decreased O-GlcNAcase
protein, so that turnover rates of O-GlcNAc may not be signiﬁcantly
altered. Certainly in other cell systems deletion of OGT leads to a re-
duction in O-GlcNAcase protein, in what seems to be an attempt to
maintain O-GlcNAc levels constant [30]. However, it is also possible
that since cardiomyocytes are essentially terminally differentiated,
that they are able to survive with very low levels of OGT until subject
to additional stress.
The lack of high afﬁnity speciﬁc inhibitors of OGT has represented
a signiﬁcant limitation in investigating the role of O-GlcNAc on cardi-
omyocyte function. Walker and colleagues identiﬁed potential OGT
inhibitors, using in vitro high throughput screening approaches
[105]. These compounds were subsequently commercially available
as OGT inhibitors (TimTec, LLC); however, while there have been
some reports in cell-based systems demonstrating the effectiveness
of these compounds in lowering O-GlcNAc levels [39,106], they
have not yet been fully validated as OGT inhibitors and thus should
be used with caution. Indeed our experience with these compounds
in decreasing O-GlcNAc levels cardiomyocytes have been unsuccess-
ful and we found that in an isolated perfused heart model as little of
5 μM of “TT04” resulted in a signiﬁcant decline in cardiac function
(Chatham, data not shown). Recently, Gloster et al. [107] described
a novel sulphonated UDP-GlcNAc analog, which inhibited OGT in
vitro with Ki of 8 μM and signiﬁcantly lowered O-GlcNAc levels in
COS-7 cells. Clearly further studies are needed to better characterize
such inhibitors, but if their speciﬁcity can be fully validated and any
effects on other glycosylation reactions characterized, the availability
of these or similar compounds could be a useful addition for the phar-
macological modulation of cardiomyocyte O-GlcNAc turnover.
4. Identifying and characterizing O-GlcNAcylated proteins
4.1. Probing for protein O-GlcNAc modiﬁcation with antibodies, enzy-
matic labeling, and metabolic labeling
While it is increasingly appreciated that O-GlcNAcylation is an
abundant PTM modiﬁcation it has been very difﬁcult to detect due
to the low stoichiometry of modiﬁcation with an estimated 5–10% oc-
cupancy at a particular site [108]; the fragile nature of the O-linkage
during tandem mass spectrometric (MS/MS) sequencing, and thelack of tools available to study this modiﬁcation. However, recent
breakthroughs in enrichment strategies and mass spectrometric se-
quencing approaches have greatly facilitated the unambiguous identiﬁ-
cation of O-GlcNAc modiﬁed peptides. These techniques are revealing
the ubiquitous and dynamic nature of this posttranslational modiﬁca-
tion and provide direct evidence that this previously overlooked modi-
ﬁcation provides an additional layer of posttranslational regulation of
protein function (Table 1).
Pan-speciﬁc anti-O-GlcNAc antibodies (CTD110.6, Pierce; RL2
Covance) have proven invaluable for monitoring changes in global
protein O-GlcNAc modiﬁcation by immunoblotting or for probing
for the presence of the modiﬁcation on a speciﬁc protein of interest.
However, these antibodies vary greatly in their speciﬁcity and sensi-
tivity toward different OGT substrates and thus recognize only a sub-
set of O-GlcNAc modiﬁed proteins. To overcome this limitation, Teo et
al. [109] have recently generated a suite of monoclonal anti-O-GlcNAc
antibodies, now available from Millipore, which were combined for
the immunoprecipitation of a more comprehensive pool of O-GlcNAc
modiﬁed proteins. Identiﬁcation of these proteins by mass spectrome-
try revealed over 200 candidate O-GlcNAc modiﬁed proteins [109].
These new antibodies represent much needed new tools that when
coupled to MS/MS should facilitate the simultaneous identiﬁcation of
both the modiﬁed protein and the sites of modiﬁcation.
Recent developments in chemoenzymatic techniques, where the
O-GlcNAc moiety is enzymatically tagged with a chemically reactive
handle, are enabling large-scale mass spectrometry-based proteomic
analyses of O-GlcNAc modiﬁed proteins. The enzymatic transfer of
[3H] galactose by β-1,4-galactosyltransferase (GalT), was originally
utilized as a sensitive and deﬁnitive alternative to western blotting
with antibodies or HRP-conjugated lectins to conﬁrm that a protein
of interest possesses the O-GlcNAc modiﬁcation [110]; however, the
catalytic activity of GalT is now being exploited for chemoenzymatic
tagging of GlcNAc using a genetically engineered GalT1 (Y298L) en-
zyme which accommodates larger chemically reactive analogs of
UDP-galactose, UDP-N-azido-acetylgalactosamine (UDP-GalNAz) or
UDP-keto-galactose [111]. Once the azido-sugar is incorporated it
is reacted by azide-alkyne Huisgen cycloaddition (“click chemis-
try”) in the presence a copper catalyst with biotinylated or other-
wise functionalized tags thereby enabling visualization and afﬁnity
puriﬁcation [112]; speciﬁcity for O-GlcNAc is obtained by cleaving
N-linked glycoproteins with PNGase F. This approach has been uti-
lized to identify 32 putative O-GlcNAc modiﬁed proteins [113].
Cell membranes are permeable to per-O-acetylated N-
azidoacetylglucosamine (Ac4GlcNAz), which once inside the cell is
deacetylated to GlcNAz by intracellular esterases; this approach has
been developed to incorporate chemically reactive sugars into O-
GlcNAcylated proteins in intact cells. Initially endogenous enzymes
in the GlcNAc salvage pathway were exploited to convert GlcNAz to
UDP-GlcNAz and GlcNAz is then transferred to serine and threonine
residues of substrate proteins by OGT. However, to overcome the low
level of incorporation of GlcNAz into proteins, Bertozzi and coworkers
have used N-azidoacetylgalactosamine (GalNAz) as a source of GlcNAz
for metabolic labeling [114]; GalNAz can be converted to UDP-GlcNAz
by UDP-galactose 4′-epimerase (GALE); following epimerization, UDP-
GlcNAz is incorporated into O-GlcNAcmodiﬁed proteins byOGT. This ap-
proach appears to be much more robust for the metabolic labeling of O-
GlcNAcmodiﬁed proteins [115]. The resulting azido sugar is then reacted
with phosphine containing functionalized linkers for the enrichment and
detection of GlcNAz containing proteins [116,117]. Pratt and colleagues
recently published a modiﬁcation of the metabolic labeling strategy,
where the GlcNAc analog contains a reactive alkyne (GlcNAlk) rather
than an azide. The UDP-GlcNAlk is less susceptible to epimerization to
the UDP-galactosamine analog and can be reacted by click chemistry
with azide containing probes [118].
One drawback to chemoenzymatic and metabolic labeling is that
the biotin-tagged O-GlcNAc modiﬁed peptide itself is rarely identiﬁed
Table 1
Methods utilized for the characterization of O-GlcNAc modiﬁed proteins.
Methodology for the enrichment and







References Tissue or cell type
Anti-O-GlcNAc immunoprecipitation
and detection by LC–MS/MS with CID or ETD.
Yes (215) No Yes [109] HEK293 cells
Yes (51) No Yes (SILAC) [162] Cos-7 cells
Lectin Weak Afﬁnity Chromatography (LWAC)
and detection by LC MS/MS with ETD.
Yes Yes (145) [123] Brain cortex
Yes Yes (58) [124]⁎ Brain cortex
Yes Yes Yes (iTRAQ) [126] Brain
Yes (62) Yes (142) Yes (SILAC) [128] Embryonic stem cells
Chemoenzymatic labeling: enzymatic
incorporation of a reactive sugar
analog followed by click chemistry.
Detection by LC–MSMS with CID or ETD.
Yes (25) No [163] Brain
Yes (20) No [164] Xenopus oocytes
Yes (pilot study) Yes (ETD) [165] Brain
Yes (32) No [113] MCF-7 cells
Yes (25) Yes (BEMAD) Yes (iTRAQ) [127] Erthyrocytes
Chemoenzymatic labeling: enzymatic
incorporation of a reactive sugar analog
followed by click chemistry with a photocleavable
biotin linker. Detection by LC MS/MS with ETD.
Yes (64) Yes (141) Yes (SILAC) [125]⁎ Hela cells
Metabolic labeling in intact cells followed by
gel-based separation and LC–MS/MS
Yes (199) No Yes [116] Hela cells
Yes (pilot study) No No [115] Jurkat cells
Yes (374) No No [118] NIH–3T3 cells
Asterisk indicates studies amenable to simultaneous identiﬁcation of the sites of phosphorylation.
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yield a list of putative candidate proteins for which the presence
and site(s) of O-GlcNAc modiﬁcation must be conﬁrmed in further
studies; however, adaptations of the chemoenzymatic labeling strat-
egy, which permit mapping the sites of O-GlcNAc modiﬁcation are
described below. A chemoenzymatic labeling approach has also
been developed to monitor dynamic changes in the stoichiometry of
O-GlcNAc modiﬁcation on a protein of interest [119]. This involves la-
beling O-GlcNAc with a large tag that increases the molecular weight
of the protein sufﬁciently to be resolved by SDS-PAGE. While this ap-
proach does not reveal the percent occupancy of O-GlcNAc modiﬁca-
tion at a particular amino acid, it offers a mechanism to screen for
ligands or physiological conditions that inﬂuence the extent of
mono-, di-, or tri-O-GlcNAc modiﬁcation of a given protein. This ap-
proach provides an alternative to using site-speciﬁc anti-O-GlcNAc
antibodies, high-resolution mass spectrometry, or radiolabels for the
interrogation of crosstalk between O-GlcNAc and other posttransla-
tional modiﬁcations.
4.2. Detection of the sites of O-GlcNAc modiﬁcation by tandem mass
spectrometry (MS/MS)
The standard approach used to identify sites of posttranslational
modiﬁcation, is to digest the protein of interest using trypsin or
other proteases. The resulting peptides are fragmented and peptide
sequence and site(s) of modiﬁcation can then be identiﬁed from the
fragmentation pattern of the peptide by MS/MS. The O-GlcNAc mod-
iﬁcation, however, is not stable during conventional MS/MS ap-
proaches; upon collision with gas molecules, the GlcNAc moiety is
lost from the Ser/Thr side chain prior to fragmentation of the peptide
backbone precluding direct detection of the site of modiﬁcation. Thus,
O-GlcNAc as well as other fragile modiﬁcations go undetected during
routine mass spectrometric analysis. The reproducible neutral loss of
the monosaccharide from the peptide and/or generation of the GlcNAc
oxonium ion (204.2 Da) may indicate the presence of an O-GlcNAc
modiﬁed peptide and themass spectrometer can be programmed to ac-
quire additional data on peptides that exhibit this behavior [108]; nev-
ertheless, the speciﬁc modiﬁcation site cannot be identiﬁed.
Recent advances in alternative fragmentation approaches, elec-
tron capture dissociation (ECD) and electron transfer dissociation
(ETD), permit sequencing of peptides with fragile modiﬁcations,such as O-GlcNAc [120]. The availability of ETD capability on commer-
cially available ion trap and Orbitrap instruments and the continued
development of algorithms for searching ETD MS/MS data against
protein databases are enabling detection of this evasive modiﬁcation
[121,122]. With a mass spectrometric method now available that allows
direct identiﬁcation of O-GlcNAc modiﬁed peptides and unambiguous
determination of the site of modiﬁcation, the remaining challenge is se-
lectively enriching O-GlcNAc modiﬁed peptides from complex mixtures
to overcome the limited dynamic range of the instrumentation.
4.3. Enrichment of O-GlcNAcylated peptides for ETD MS/MS
To facilitate the identiﬁcation of the sites of modiﬁcation, O-
GlcNAcylated peptides can be immunoprecipitated with pan-O-GlcNAc
antibodies, enriched with wheat germ agglutinin (WGA) or succinylated
WGA lectins, or afﬁnity puriﬁed following chemoenzymatic labeling. The
older O-GlcNAc antibodies, RL2 and CTD110.6, were of limited utility
for immunoprecipitation due to either recognition of a limited num-
ber of proteins or relatively poor elution efﬁciency; however the
newer antibodies appear to have improved properties for immuno-
puriﬁcation of O-GlcNAcylated peptides and proteins [109].
During lectin weak afﬁnity chromatography, a longWGA agarose col-
umn (N3m in length) is utilized to separate O-GlcNAcmodiﬁed peptides
fromunmodiﬁed peptides [123,124].WGA lectin interacts predominately
with the N-acetylhexosamines (HexNAc), N-acetylglucosamine (GlcNAc)
andN-acetylgalactosamine (GalNAc). Highly glycosylated peptides are
retained on the column while the migration of monosaccharide
containing peptides is weakly retarded. Mass spectrometric analy-
sis of the enriched mono-glycosylated peptides reveals the site of
attachment at Asn or Ser/Thr but does not distinguish GlcNAc
from GalNAc. The advantage of this approach is its simplicity and
coupled with electron transfer dissociation MS/MS, the sites of O-
linked HexNAc are directly identiﬁed without the need for enzy-
matic labeling or chemical derivatization. Recent studies have also
coupled this enrichment approach to quantitative proteomic strat-
egies to identify sites of O-GlcNAc modiﬁcation that are dynamical-
ly regulated [125,126].
Adaptations to the chemoenzymatic tagging approach, implemented
speciﬁcally to enable mass spectrometric identiﬁcation of biotin-tagged
O-GlcNAc modiﬁed peptides, offer an alternative enrichment strategy
that can be coupled to quantitative proteomic methodology. To
Fig. 2. Acute and transcriptional regulation of cardiac metabolism mediated by the
hexosamine biosynthesis pathway (HBP) and O-GlcNAc. Flux through the HBP is regu-
lated by glutamine-D-fructose 6-phosphate amidotransferase (GFAT) and is dependent
on the availability of glucose and glutamine. O-GlcNAc transferase (OGT) is subject to
both O-GlcNAcylation (green circles) and phosphorylation (red circles) mediated by
insulin, both of which have been reported to increase its activity. AMPK, which is
well recognized as a key regulator of cellular metabolism has been reported to be a target
for O-GlcNAcylation and that this increases its activity; furthermore, GFAT has been shown
to bephosphorylatedbyAMPKalso leading to increased activity. This provides a feed forward
loop leading to a further increase inOGT activity and subsequent increase inO-GlcNAcylation.
Increases in O-GlcNAc levels can potentially acutely regulate cardiacmetabolism, not only by
modiﬁcation of AMPK, but also by O-GlcNAcylation of other key mediators of carbohydrate
and fatty acid metabolism. A number of transcription factors, which play a critical role in
the longer-term regulation of metabolism, are also known to be O-GlcNAcylated.
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din beads and the inefﬁcient backbone fragmentation of biotinylated pep-
tides during MS/MS, peptides can be released from streptavidin beads by
base catalyzed β-elimination [127] or by the use of a photocleavable bio-
tinylated alkyne crosslinker [125]. One caveat of β-elimination is that
this results in the release of peptides that no longer contain an O-
GlcNAc tag, thus further studies must be performed to validate
the site(s) of modiﬁcation. In contrast, following photolysis the
photocleavable linker leaves behind a tag that provides a signature frag-
mentation pattern by MS/MS and enables assignment of the site of
modiﬁcation. Although the chemoenzymatic tagging approach requires
multiple sample preparation steps, advantages of this workﬂow include
the ability to couple this approach to established quantitative proteomic
procedures.
The use of isobaric tags (iTRAQ) or stable isotopic labeled amino
acids in cell culture (SILAC) prior to enrichment of O-GlcNAcylated
peptides permits the simultaneous identiﬁcation of the site and rela-
tive quantitation of the extent of O-GlcNAc modiﬁcation following a
stimulus [126,128,129]. These studies require a high mass accuracy
tandem mass spectrometer with the capability to fragment peptides
by collision induced dissociation and electron transfer dissociation.
The ability to couple quantitative proteomic approaches to the site-
speciﬁc identiﬁcation of O-GlcNAc modiﬁcation will permit the unbi-
ased discovery of the temporal dynamics and regulation of this mod-
iﬁcation during signal transduction. While alterations in the patterns
of protein O-GlcNAc modiﬁcation have been observed under varying
physiological conditions in the heart, to date these proteins have
not been identiﬁed. As sites of protein O-GlcNAc modiﬁcation are
published, they are made publically available in the Cell Signaling
Phosphosite database [130] and dbOGAP [131]. The dbOGAP reposito-
ry also contains information regarding known sites of phosphorylation
that are in close proximity to the sites of O-GlcNAc modiﬁcation. Large
scale site-mapping experiments are revealing a loose consensus se-
quence and this information has been utilized to generate an algorithm
for predicting sites of O-GlcNAcmodiﬁcation [131]. It has been estimat-
ed that with the emergence of these newMS and enrichment strategies,
the total number of O-GlcNAc modiﬁcation sites mapped over the past
2 years is greater than those identiﬁed during the past 20 years [3].
5. O-GlcNAcylation as a metabolic sensor and regulator
The HBP has long been recognized as a glucose-sensing pathway
[6,26,132], but as noted earlier since it intersects with several key
metabolic pathways it might be more accurately characterized as nu-
trient or metabolic sensing pathway. Increased ﬂux through the HBP
was ﬁrst linked to the development of cellular insulin resistance in
1991 [61] and has been further supported by studies demonstrating
that glucosamine infusion in vivo resulted in skeletal muscle insulin
resistance [93,133,134] and also that GFAT overexpression in mice
leads to insulin resistance [135,136]. Glucosamine induced insulin re-
sistance is also mediated by increased O-GlcNAcylation of IRS-1 and
IRS-2 [134]. Increased cellular O-GlcNAc levels also decreased insulin
stimulated GLUT4 translocation, reduced insulin-stimulated phosphor-
ylation of IRS-1 and Akt as well as increased O-GlcNAc modiﬁcations of
GLUT4, IRS-1 and Akt2 [137]. It isworth noting, however, that at the cel-
lular level increased O-GlcNAcylation does not appear to be essential for
the development of glucose/insulin-induced insulin resistance [138].
The syntaxin 4 binding protein, Munc18c is also modiﬁed by O-
GlcNAc [139]; Munc18c contributes to membrane fusion events, in-
volved in insulin-stimulated GLUT4 translocation and its modiﬁcation
by O-GlcNAc attenuated the response to insulin [139]. Chronic activa-
tion of the HBP also resulted in O-GlcNAcylation of AMPK, which was as-
sociated with increased activity and increased fatty acid oxidation [140].
Taken together, these data support the concept of O-GlcNAcylation as
glucose sensingmechanism, and that elevated O-GlcNAc levels on sever-
al different key regulatory proteins, acts in a feedback manner toattenuate glucose entry. This is also consistent with the widely accepted
notion that chronically elevated cellular O-GlcNAc levels is a contribut-
ing factor to the etiology of insulin resistance as well as a key mediator
of glucose toxicity associated with the adverse effects of diabetes on
numerous tissues including cardiomyocytes [5,21,27,55]. It is of note
that GFAT which regulates glucose ﬂux into the HBP, is phosphorylated
and activated by AMPK [66] and since O-GlcNAcylation is reported to
increase AMPK activity, this could represent a feed forward mecha-
nism, which if sustained may also contribute to O-GlcNAc mediated
glucotoxicity (Fig. 2).
While the studies highlighted above demonstrate a clear link between
theHBP, O-GlcNAcylation levels and glucosemetabolism it is striking that
the focus is primarily on relatively long term regulationwith an emphasis
on the pathogenesis of insulin resistance and glucotoxicity. However, as
noted above changes in O-GlcNAcylation can occur rapidly and we have
demonstrated that relatively acute increases in O-GlcNAc levels canmod-
ulate the responses of cardiomyocytes and the intact heart to stress and
agonist stimulation [32,47,83,84]. This raises the question as to whether
short termmodulation ofO-GlcNAc synthesis in the heart, could inﬂuence
cardiac metabolism and substrate selection. To address this question, we
recently examined the effects of glucosamine (0–10 mM) on substrate
utilization in the intact heart perfused with physiologically relevant
concentrations of glucose, lactate, pyruvate, palmitate and insulin [90].
Perfusion for 60 minwith as little as 50 μMglucosamine signiﬁcantly in-
creased both UDP-GlcNAc and O-GlcNAc levels. While there are poten-
tial pathways for glucosamine metabolism, which could lead to an
increase in glycolysis [141,142], we found that glucosamine had no ef-
fect on either glucose oxidation or glycolytic ﬂux [90]. Surprisingly,
however, we found a signiﬁcant increase in palmitate oxidation with a
concomitant decrease in lactate and pyruvate oxidation reaching a
maximal effect at 100 μM glucosamine. In contrast to Luo et al., who
reported that glucosamine stimulated fatty acid oxidation in cultured
adipocytes was associated with increased AMPK and ACC phosphoryla-
tion [140], we observed no effect of glucosamine on either AMPK or ACC
phosphorylation. On the other hand, membrane levels of FAT/CD36,
whichplays a key role in fatty acid transport in the heart,were signiﬁcant-
ly increased; furthermore, preliminary data suggested that FAT/CD36 is
also a potential target for O-GlcNAcylation [90].
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model of hypertension, which expresses a different cd36 mRNA com-
pared to Wistar controls rats and in the SHR heart, CD36 protein levels
at plasma membrane are reduced [143]. Earlier studies by Des Rosiers
and colleagues showed that the contribution of exogenous long-chain
fatty acids to β-oxidation was signiﬁcantly reduced in hearts from SHR
rats [144] and they recently reported that this could be due to alterations
in post-translational modiﬁcations of CD36 protein including changes in
O-GlcNAc modiﬁcation [145]. Consistent with our observations, they
found that in hearts from control Wistar rats, 0.5 mM glucosamine in-
creased fatty acid oxidation N2 fold, but had no effect on fatty oxidation
in hearts fromSHRs, despite the fact that overall O-GlcNAc levelswere in-
creased to the same extent. They also reported that based on the pre-
dicted sequences for the wild-type and mutant CD36, the mutant CD36
had fewer potential sites for post-translational modiﬁcation, including
reduced O-GlcNAc modiﬁcation sites. Further support for the HBP and
by extension O-GlcNAc in regulating cardiac metabolism, was provided
by the observation that glutamine, which is required for GFAT activity
(Fig. 1), also increases long-chain fatty acid metabolism and this can be
reversed by inhibition of the HBP with azaserine [146]. Taken together
these studies suggest a novel mechanism by which the HBP and O-
GlcNAcylation could play a role in the acute regulation of cardiacmetab-
olism. Speciﬁcally, these data have led us to postulate that an increase in
glucose ﬂux through the HBP, resulting in increased O-GlcNAcylation of
CD36, leads to increased fatty acid transport and oxidation, which
would have an indirect feedback effect on decreasing carbohydrate
oxidation.
Young and colleagues have shown that cardiac metabolism exhibits
timeof day dependent changes in both fatty acid and glucosemetabolism
which was associated with diurnal variations in total protein O-
GlcNAcylation and abolished in hearts from cardiac clock mutant
(CCM) mice [147]. Speciﬁcally they found that during the active phase
there was increased myocardial protein O-GlcNAcylation suggesting in-
creased ﬂux of glucosyl moieties through the hexosamine biosynthetic
pathway. Thus the cardiomyocyte circadian clock regulates nonoxidative
fatty acid (i.e. triglyceride) and glucose (i.e. glycogen and O-GlcNAc)me-
tabolism [148]. They also found that increased protein O-GlcNAcylation
results in altered gene and protein expression of cardiomyocyte circadian
clock components, as well as protein O-GlcNAcylation of CLOCK, raising
the possibility that non-oxidative glucosemetabolism is an integral com-
ponent of the cardiomyocyte circadian clock, potentially mediated via
protein O-GlcNAcylation.
Yang et al., [74] provided further support for a close link between O-
GlcNAc and metabolic regulation, by showing that insulin treatment
leads to translocation of OGT from the nucleus to the plasmamembrane,
where it catalyzes the O-GlcNAcylation of key components of the insulin
signaling pathway thereby attenuating insulin signal transduction. It was
postulated that this represented one of the mechanisms contributing to
O-GlcNAcmediated insulin resistance; however, these data also suggests
a novel feedback loop, which could contribute to the short-term regula-
tion of cellular metabolism. While further studies are clearly needed to
demonstrate that HBP ﬂux and O-GlcNAc turnover play a central and co-
ordinated role in regulating cardiac metabolism it is clear that there is a
close relationship between theHBP, O-GlcNAcylation and both acute reg-
ulation of myocardial substrate utilization as well as transcriptionally
mediated regulation as summarized in Fig. 2.
6. Mitochondria as an integrator of redox and O-GlcNAc signaling
It is well established that mitochondria play a central role in inte-
grating cellular energy metabolism, redox signaling and cell survival
pathways; however, the role of O-GlcNAcylation in regulating these
processes is poorly understood. The notion that mitochondrial pro-
teins might be potential targets for O-GlcNAc modiﬁcation was ﬁrst
raised by the identiﬁcation of a speciﬁc mitochondrial isoform of
OGT (mOGT), which is localized to the inner membrane ofmitochondria and contains mitochondrial targeting sequence [72].
While initial reports suggested that mOGT had either limited catalytic
activity or that substrates for OGT in the mitochondria were very lim-
ited [11,72], more recently, a number of studies have suggested that
O-GlcNAcylation of mitochondria proteins contributes to both to
acute cardioprotection [33,38] as well as mitochondrial dysfunction
and increased programmed cell death [45,110].
Some of the ﬁrst evidence to suggest that O-GlcNAc had a direct effect
onmitochondrial functionwas the demonstration that acute increases in
O-GlcNAc levels in the heart or in isolated cardiomyocytes, attenuated
mPTP opening, a critical step in the initiation of programmed cell death
[33,38,39,149]. For example, mitochondria isolated from hearts of
mice treated with the O-GlcNAcase inhibitor, PUGNAc were resistant
to Ca2+-inducedmPTP formation as assessed bymitochondrial swelling
assay. Furthermore, overexpression of OGT in neonatal cardiomyocytes
also decreased Ca2+-inducedmitochondrial swelling; whereas, OGT in-
hibition increasedmitochondrial swelling [38,39]. VDAC has been iden-
tiﬁed as a potential O-GlcNAc target and it has been hypothesized that
O-GlcNAcylation of VDAC preservesmitochondrial integrity by interfer-
ing with mPTP formation [38]. In addition we have shown that increas-
ing overall O-GlcNAc levels either by increasing O-GlcNAc synthesis with
glucosamine, and increasedOGT expression or decreasingO-GlcNAc deg-
radation by inhibiting O-GlcNAcase all attenuated H2O2-induced loss of
mitochondrial membrane potential and cyctochrome c release [33],
which was associated with increased mitochondrial Bcl-2 levels. Since
Bcl-2 inhibits the mPTP opening possibly by interaction with VDAC, one
of the putative components of mPTP [150,151]. However, given that
VDAC is not required for mPTP opening and the continued uncertainty
regarding the molecular composition of the mPTP [152], whether O-
GlcNAcylation of VDAC directly contributes to the attenuation of mPTP
opening, has yet to be veriﬁed.
Despite the apparent protective effects associated with increasingmi-
tochondrial O-GlcNAc levels, it was initially reported that overexpression
ofmOGTwas toxic to cells [72]. More recently, Shin et al. [110] developed
an inducible expression system enabling selective expression of either
mOGTor ncOGT isoforms inmammalian cells. They reported that increas-
ingmOGT levels induced apoptosis in both a human embryonic kidney ﬁ-
broblast cell lime (EcR-293) and insulinoma derived INS-1 cell lines. The
extent to which this would be applicable to the heart or cardiomyocytes
is not known; however, given the high energetic demand of the heart
and the importance of tight control of oxidative metabolism, it is likely
that dysregulation ofmitochondrial O-GlcNAcylationwould also be detri-
mental to cardiomyocytes. Evidence in support of this was provided by
Hu et al. [45], who reported that hyperglycemia induced mitochondrial
dysfunction in cardiomyocytewasmediated via O-GlcNAcylation ofmito-
chondrial proteins. Importantly they identiﬁed several mitochondrial
proteins as targets for O-GlcNAc modiﬁcation that are members of re-
spiratory complexes, such as NDUFA9 of complex I, and the mitochon-
drial DNA-encoded, subunit I of Complex IV (COX I). They also found
that hyperglycemia induced increases inmitochondrial O-GlcNAc levels
resulted in impaired activity of Complex I, III and IV and that this could
be reversed by increasing expression of O-GlcNAcase.
The study by Hu et al. [45] was the ﬁrst to show that in cardiac mi-
tochondria, proteins in the respiratory complexes are modiﬁed by O-
GlcNAc and that this may contribute to impaired function induced by
hyperglycemia. However, a number of key questions remain, including
the regulation ofmitochondrial O-GlcNAc synthesis and themechanism
by which removal of O-GlcNAc from mitochondrial proteins is cata-
lyzed. Earlier reports speculated that the very low levels of mitochon-
drial O-GlcNAcylation could be due to limited substrate availability,
i.e., UDP-GlcNAc [72]. The fact that even under basal conditions there
was evidence of mitochondrial GlcNAcylation suggests that is not the
case in the heart; however, this leaves open the question whether
UDP-GlcNAc is actively transported into mitochondria, as it is in the
ER and Golgi [153,154] and the extent to which availability of UDP-
GlcNAc is rate limiting for mitochondrial O-GlcNAc synthesis? Perhaps
Fig. 3. The intersection between O-GlcNAcylation, ROS and mitochondrial function. In
response to an acute stress (upper panel), including that induced by ROS, there is a
rapid increase in cellular and potentially mitochondrial O-GlcNAcylation as a result of
either an increased ﬂux through the hexosamine biosynthesis pathway (HBP) and/or
decreased O-GlcNAcase activity (OGA). This acute increase in O-GlcNAc levels has
been shown to improve tolerance of mitochondria to oxidative stress and attenuate
loss of mitochondrial membrane potential leading to increased cell survival. Strategies
designed to acutely augment this response have been shown to improve cell survival;
conversely decreased O-GlcNAc levels lead to decreased cell survival. Chronic increases
in cellular O-GlcNAc levels are typically associated with metabolic disease such as dia-
betes and the resulting hyperglycemia. Sustained increases in glucose levels can in-
crease O-GlcNAc synthesis by directly increasing ﬂux through the HBP as well as
indirectly, as a result of hyperglycemia induced ROS production, which has also been
shown to stimulate O-GlcNAc synthesis (lower panel). Hyperglycemia is also known
to lead to impaired mitochondrial function in part due to increased O-GlcNAcylation
of mitochondrial proteins, which could in turn further increase ROS production and
thereby in a feed forward manner continue to increase O-GlcNAc levels with an even
greater decline in mitochondrial function. This O-GlcNAc mediated impairment of mi-
tochondrial function, could then increase the vulnerability to additional stress thus
leading to increased cell death. Indeed, targeted overexpression of mitochondrial
OGT has been shown to lead to increased apoptosis.
545V.M. Darley-Usmar et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 538–549even more important for our understanding of O-GlcNAc cycling in the
mitochondria is the mechanism by which O-GlcNAc is removed from
mitochondrial proteins. Hu et al. [45] reported low levels of O-
GlcNAcase activity in mitochondria isolated from mouse hearts and
showed that increasing cellular levels of O-GlcNAcase attenuated the
hyperglycemia induced increase in mitochondrial O-GlcNAc levels.
However, as far as we are aware, no mitochondrial protein has been
shown to have the hexosaminidase activity required to catalyze the re-
moval of O-GlcNAc from proteins; in other words to date only one half
of the O-GlcNAc cycle in the mitochondria, namely mOGT has been
identiﬁed.
While it is well established that hyperglycemia leads to increased
O-GlcNAc levels in multiple cells and organs including the intact heart
and cardiomyocytes, it is important to note that unlike glucosamine
which is primarily metabolized via the HBP, increasing glucose levels
has multiple effects, including increased oxidative stress. Indeed it
has been reported that hyperglycemia leads to increase generation
of mitochondrial superoxide and it is this increase in reactive oxygen
species (ROS), which leads to activation of the HBP and increased O-
GlcNAc synthesis [48,49]. It has also been proposed that mitochondri-
al superoxide inhibits GAPDH, which further contributes to the in-
creased ﬂux of glucose through the HBP, by attenuated glycolysis
[48,49]. However, since relatively little is known regarding the regula-
tion of GFAT, OGT, and O-GlcNAcase, we cannot rule out the possibility
that ROS could directly modulate their activities. Thus, hyperglycemia
has the potential to increase O-GlcNAc levels both by directly increasing
glucose ﬂux through the HBP as well as by ROS mediated increase in
pathways leading to O-GlcNAc synthesis.
While there are clearly many gaps in our knowledge regarding the
regulation of mitochondrial O-GlcNAcylation it is increasingly evident
that mitochondrial proteins are targets for O-GlcNAc modiﬁcation.
Our current understanding of effects of altered O-GlcNAc levels on
mitochondria function is summarized in Fig. 3. There is no doubt that
in response to an acute stress, including oxidative stress there is an in-
crease in cellular O-GlcNAc levels, and pharmacological approaches to
augment this increase either by activating HBP ﬂux or inhibiting O-
GlcNAcase activity, increases tolerance ofmitochondria to oxidative stress
and thereby improves cell survival. In cardiomyocytes this increased tol-
erance to oxidative stress as discussed above is associated with increased
O-GlcNAc levels on speciﬁc mitochondrial proteins, such as VDAC. In the
case of a chronic stress such as that seen with hyperglycemia, there can
be both a direct increase in O-GlcNAc synthesis due to increase glucose
metabolism via the HBP as well as activation of the HBP mediated by in-
creased mitochondrial ROS. Under sustained conditions, this has the po-
tential to establish a feed forward loop where impaired mitochondrial
function leads to greater ROS production and this could further augment
the increase in O-GlcNAcylation, contributing to further mitochondrial
dysfunction and ultimately cell death. Hu et al. [45] demonstrated that
in cardiomyocytes there is a clear association between hyperglycemia, in-
creased O-GlcNAcylation of key respiratory chain proteins and impaired
mitochondrial function.
The above discussion has focused on direct O-GlcNAc modiﬁcation
of mitochondrial proteins; however, it is should be recognized that
changes in O-GlcNAc turnover may have indirect effects on mito-
chondrial function via O-GlcNAcylation of proteins that could inﬂu-
ence mitochondrial function, but are not themselves mitochondrial
proteins. One potentially intriguing example is GSK-3β, where in-
creased O-GlcNAcylation attenuates its activity [76]. Furthermore,
the cytoprotection associated with stress-induced increase in O-
GlcNAc was reported to be due to increased heat shock protein ex-
pression as a consequence of O-GlcNAc-mediated inhibition of GSK-
3β [30]. This is may be particularly relevant in the context of ischemic
cardioprotection where GSK-3β is a major convergence point for mul-
tiple cardioprotection strategies as well as a key effector for activation
of downstream targets [155–157], including attenuation of the mito-
chondrial permeability transition pore (mPTP).7. O-GlcNAc and redox cell signaling
In addition to being increased in response to various stress stimuli
the generation of reactive oxygen species (ROS) is an inevitable
byproduct of normal mitochondrial metabolism. Rather than just
leading to non-speciﬁc modiﬁcations of lipids and proteins, it is wide-
ly recognized that ROS and reactive nitrogen species (RNS) play an in-
tegral role in regulating redox cell signaling pathways [158,159]. An
emerging concept in redox biology is the concept of “redox tone”
[158,159], where cell signaling, metabolism, and cell survival outcomes
are linked to the antioxidant and thiol status of cells. Interestingly, sev-
eral links between O-GlcNAc protein modiﬁcation and oxidative stress
suggest that O-GlcNAc signaling may represent an important mecha-
nism that integrates both metabolic and redox signaling and thereby
modulate redox tone.
One example of the intersection between redox signaling and
O-GlcNAc is nitric oxide synthase (NOS), which is subject to both
phosphorylation and O-GlcNAcylation and is responsible for the
generation of nitric oxide (NO), one of the most widely recognized re-
active species involved in redox signaling. Endothelial NOS (eNOS) is
activated by Akt-mediated phosphorylation of Ser1177, which in-
creases its activity; however this same site it also a target for O-
GlcNAc modiﬁcation, leading to lower activity and decreased NO pro-
duction [49]. The interaction between O-GlcNAc and redox signaling
can also occur at the transcriptional level; for example the transcrip-
tion factor FoxO1, which is activated by O-GlcNAcylation [160] also
regulates the transcription of oxidative stress responsive enzymes,
such as catalase and MnSOD. Taken together these observations high-
light the potential role of O-GlcNAc turnover integrating both acute
and transcriptional responses to oxidative stress thereby playing a
key role in regulating redox signaling.
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Our understanding of the potential importance of protein O-
GlcNAcylation in mediating the function and stress response of the
heart and vascular system has only emerged over the past 5–
10 years. This is highlighted by the fact that a PubMed search combin-
ing heart/cardiac/vascular with O-GlcNAc yields a total of only 65 pa-
pers, of which 51 or 78% have been published in the last 5 years.
Studies to date have demonstrated that consistent with other tissues
and organs changes in overall levels of O-GlcNAcylation occur rapidly
in response to various stimuli emphasizing the dynamic nature of O-
GlcNAc synthesis and removal. In agreement with much of the earlier
literature on O-GlcNAcylation in other biological systems, increased
O-GlcNAc levels have been linked to the adverse effects of metabolic
disease, especially diabetes, on both cardiomyocyte and vascular
function. There is also emerging evidence to suggest that dysregula-
tion in O-GlcNAc cycling in vascular smooth muscle may be associat-
ed with hypertension; however, further work is needed to establish a
true causal relationship. There is also substantial evidence demon-
strating that acute augmentation of cardiac O-GlcNAc levels either
by increasing synthesis or inhibiting degradation affords signiﬁcant
ischemic cardioprotection and this has been demonstrated at the cel-
lular level, the perfused heart and in vivo. While much of the empha-
sis on studies of O-GlcNAcylation in the heart have been focused on
its role in mediating the response to various pathophysiological stres-
ses, recent data has emerged demonstrating that acute and relatively
subtle changes in O-GlcNAcylation can directly modulate cardiac me-
tabolism, illustrating that it also contribute to the regulation of nor-
mal physiological processes.
Parallels are frequently drawn between phosphorylation and O-
GlcNAcylation, and while this is not surprising given that both re-
spond rapidly to a wide range of stimuli and modify similar protein
residues via an O-linkage, there are however some notable differ-
ences. The most obvious difference is that in contrast to the hundreds
of kinases and phosphatases involved in regulating phosphorylation,
there is a single OGT responsible for adding O-GlcNAc to proteins
and single OGA to remove O-GlcNAc. This raises a key question as to
how the kind of speciﬁcity associated with phosphorylation can be
achieved with O-GlcNAcylation? One putative mechanism is the mul-
tiple TPRs in the N-terminal domain of OGT, which play a key role in
recognition and activation of speciﬁc protein targets [59,76]. In sup-
port of this there are clear examples of OGT forming transient com-
plexes with key protein targets in response to speciﬁc stimuli
[74,87]; however considerable work remains, to better understand
the activation and regulation of the formation of these protein
complexes.
Given that O-GlcNAcylation appears to be as abundant as phosphory-
lation, it is perhaps surprising that it is not as widely studied. It is worth
remembering, however, that the recognition of phosphorylation as an
importantmechanism for regulating protein function tookmany decades
to be fully appreciated. As discussed by Krebs in his 1992 Nobel lecture,
while the discovery of serine/threonine phosphorylation occurred as
early as 1933; it was only by 1968 that it was recognized that phosphor-
ylation could be regulated by extracellular stimuli [161] and by 1976,
43 years after it was ﬁrst described, the number of enzymes known to
undergo phosphorylation/dephosphorylation was over 20 [161]. It is
now a little over 25 years since protein O-GlcNAcylation was ﬁrst de-
scribed [2] and currently more than 1000 proteins have been identiﬁed
as being targets for this modiﬁcation (http://cbsb.lombardi.georgetown.
edu/statistic.php). One reason why studies of O-GlcNAcylation have not
emergedmore rapidly is due, at least in part, because that it is a lowmo-
lecular weight modiﬁcation and unlike phosphorylation is uncharged,
therefore does not lead to gel shifts. In addition it is very labile not only
in traditional MS analyses, but also if tissue samples are processed with-
outO-GlcNAcase inhibitors, it is readily lost fromproteins, aswould occur
with phosphorylation in the absence of phosphatase inhibitors. Finally,the lack of available reagents has also been ahindrance; until very recent-
ly, there were only 2 commercially available pan O-GlcNAc antibodies
(CTD110.6 and RL2) and antibodies to OGT and OGA have only become
widely available in the past 3–5 years. In addition a critical limitation in
trying to elucidate O-GlcNAc dependent signaling networks is the lack
of site speciﬁc O-GlcNAc antibodies. Antibodies generated against syn-
thetic O-GlcNAcylated peptides have provided site-speciﬁc (S1011-O-
GlcNAc IRS-1 [108]) and pan-speciﬁc (CTD110.6) antibodies; however,
the synthesis and deprotection of O-GlcNAc peptides is signiﬁcantly
more challenging than that of phosphopeptides.
It is clear that O-GlcNAcylation is an integral component of the
complex signaling network involved in regulating cellular responses
to physiological and pathophysiological stimuli; however, it is also
equally clear that our understanding of the fundamental mechanisms
involved in regulating O-GlcNAc turnover is surprisingly limited. A
major challenge has been the lack of reliable tools, including anti-
bodies, which are taken for granted in the investigation of many
PTMs; however, as the methods for identifying and characterizing
O-GlcNAcylated proteins are continuing to improve and become
more widely available, it is anticipated that there will be an increasing
number of investigators driven to elucidate more fully the role of O-
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